AlphaWire

newswire

Astra Zeneca shares fall as much as 7% on report of merger talks with Bristol Myers Squibb

2026-08-03·newswire-us-stock-084001
Astra Zeneca shares fall as much as 7% on report of merger talks with Bristol Myers Squibb.

AstraZeneca shares fell as much as 7% after reports that the U.K.'s largest drugmaker was in talks with U.S. peer Bristol Myers Squibb on a major transaction that could value the combined companies at about $400 billion if completed. AstraZeneca declined to comment.

Bristol Myers Squibb did not immediately respond to a request for comment outside regular business hours. The companies have reportedly been discussing a potential merger for several months. If completed, it would be one of the largest pharmaceutical transactions in history.

AstraZeneca's London-listed shares were recently down 6.2% in early trading, weighing on the U.K.'s blue-chip FTSE 100 index, which was broadly flat. At the start of Monday's trading session, AstraZeneca had a market capitalization of $264 billion.

That figure has risen steadily over the past decade as the company developed a strong pipeline of new medicines after Chief Executive Officer Soriot took over in 2012. AstraZeneca is targeting $80 billion in sales by 2030, up from $58.7 billion last year. Bristol Myers Squibb had a market capitalization of about $133 billion.

Details of the discussions remain unclear, and people familiar with the matter said the transaction may still fail to materialize. Analysts were nevertheless puzzled by the report. “Given AstraZeneca’s strong performance in growth and innovation, we are somewhat puzzled,” Jefferies analysts wrote Monday morning.

“Of course, the financial benefits could look attractive, and greater cash generation might support additional research and development. But if there is one company that does not need financial engineering, it is AstraZeneca.”

#Stocks #Semiconductors

Full text

Astra Zeneca shares fall as much as 7% on report of merger talks with Bristol Myers Squibb

AstraZeneca shares fell as much as 7% after reports that the U.K.'s largest drugmaker was in talks with U.S. peer Bristol Myers Squibb on a major transaction that could value the combined companies at about $400 billion if completed. AstraZeneca declined to comment. Bristol Myers Squibb did not immediately respond to a request for comment outside regular business hours. The companies have reportedly been discussing a potential merger for several months. If completed, it would be one of the largest pharmaceutical transactions in history. AstraZeneca's London-listed shares were recently down 6.2% in early trading, weighing on the U.K.'s blue-chip FTSE 100 index, which was broadly flat. At the start of Monday's trading session, AstraZeneca had a market capitalization of $264 billion. That figure has risen steadily over the past decade as the company developed a strong pipeline of new medicines after Chief Executive Officer Soriot took over in 2012. AstraZeneca is targeting $80 billion in sales by 2030, up from $58.7 billion last year. Bristol Myers Squibb had a market capitalization of about $133 billion. Details of the discussions remain unclear, and people familiar with the matter said the transaction may still fail to materialize. Analysts were nevertheless puzzled by the report. “Given AstraZeneca’s strong performance in growth and innovation, we are somewhat puzzled,” Jefferies analysts wrote Monday morning. “Of course, the financial benefits could look attractive, and greater cash generation might support additional research and development. But if there is one company that does not need financial engineering, it is AstraZeneca.”

AstraZeneca shares fell as much as 7% after reports that the U.K.'s largest drugmaker was in talks with U.S. peer Bristol Myers Squibb on a major transaction that could value the combined companies at about $400 billion if completed.

AstraZeneca declined to comment. Bristol Myers Squibb did not immediately respond to a request for comment outside regular business hours.

The companies have reportedly been discussing a potential merger for several months. If completed, it would be one of the largest pharmaceutical transactions in history. AstraZeneca's London-listed shares were recently down 6.2% in early trading, weighing on the U.K.'s blue-chip FTSE 100 index, which was broadly flat.

At the start of Monday's trading session, AstraZeneca had a market capitalization of $264 billion. That figure has risen steadily over the past decade as the company developed a strong pipeline of new medicines after Chief Executive Officer Soriot took over in 2012. AstraZeneca is targeting $80 billion in sales by 2030, up from $58.7 billion last year. Bristol Myers Squibb had a market capitalization of about $133 billion.

Details of the discussions remain unclear, and people familiar with the matter said the transaction may still fail to materialize. Analysts were nevertheless puzzled by the report.

“Given AstraZeneca’s strong performance in growth and innovation, we are somewhat puzzled,” Jefferies analysts wrote Monday morning. “Of course, the financial benefits could look attractive, and greater cash generation might support additional research and development. But if there is one company that does not need financial engineering, it is AstraZeneca.”

← Back to archive